- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03571568
Un estudio de BI-1206 en combinación con rituximab en sujetos con linfoma no Hodgkin de células B indolente
Ensayo clínico de fase 1/2a de BI-1206, un anticuerpo monoclonal contra CD32b (FcYRIIB), en combinación con rituximab en sujetos con linfoma no Hodgkin de células B indolente que ha recaído o es refractario a rituximab
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Phase 1/2a, multicenter, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab with or without acalabrutinib in subjects with indolent relapsed or refractory B-cell NHL, sub-types FL (except FL grade 3B), MZL, and MCL.
Phase 2a, consists of signal seeking cohorts followed by a randomized, parallel, two-arm dose optimization.
The trial consists of 2 main parts:
Phase 1
- Dose Escalation, with two different Arms assessing IV or SC dosing of BI-1206 in combination with rituximab, with dose escalation cohorts and selection of the IV and SC doses of BI-1206 for Phase 2a
Phase 2a
- Dose Expansion, with one expansion cohort evaluating the selected IV dose of BI-1206 in combination with rituximab
- Signal Seeking, assessing IV and SC dosing of BI-1206 in combination with rituximab and acalabrutinib. The Signal Seeking will consist of a Safety Run-in and an Expansion
- Dose Optimization to select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Erika Bågeman
- Número de teléfono: +46706126618
- Correo electrónico: erika.bageman@bioinvent.com
Copia de seguridad de contactos de estudio
- Nombre: Andres McAllister, MD, PhD
- Correo electrónico: andres.mcallister@bioinvent.com
Ubicaciones de estudio
-
-
-
Stuttgart, Alemania
- Retirado
- Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
-
-
Hesse
-
Frankfurt am Main, Hesse, Alemania
- Aún no reclutando
- Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
-
Investigador principal:
- Eckhart Weidmann, MD
-
Contacto:
- Correo electrónico: weidmann.eckhart@khnw.de
-
-
-
-
-
Curitiba, Brasil
- Aún no reclutando
- Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
-
Contacto:
- Correo electrónico: munhoz.ec@gmail.com
-
Investigador principal:
- Eduardo Munhoz, MD
-
Rio de Janeiro, Brasil
- Aún no reclutando
- Ruschel Medicina e Pesquisa Clínica
-
Contacto:
- Thaiane Alexandre, RN
- Correo electrónico: thaianealexandre@ruschelmedicina.com.br
-
Investigador principal:
- Rony Schaffel, MD
-
São Paulo, Brasil
- Aún no reclutando
- Hospital Samaritano
-
Contacto:
- Correo electrónico: carlos.chiattone@terra.com.br
-
Investigador principal:
- Carlos Chiattone, MD
-
São Paulo, Brasil
- Aún no reclutando
- Hospital Sírio-Libanês
-
Investigador principal:
- Ana Rita Da Fonseca, MD
-
Contacto:
- Correo electrónico: anaritafonsecabm@gmail.com
-
São Paulo, Brasil
- Aún no reclutando
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
Contacto:
- Camila Hinsching, RN
- Correo electrónico: camila.f@hc.fm.usp.br
-
Investigador principal:
- Juliana Pereira, MD
-
São Paulo, Brasil
- Reclutamiento
- A.C. Camargo Cancer Center
-
Investigador principal:
- Ana Costa Cordeiro, MD
-
Contacto:
- Correo electrónico: ana.cordeiro@accamargo.org.br
-
São Paulo, Brasil
- Aún no reclutando
- Hospital Amaral Carvalho
-
Contacto:
- Correo electrónico: pesquisafac.edersonmattos@gmail.com
-
Investigador principal:
- Ederson Roberto De Mattos, MD
-
São Paulo, Brasil
- Reclutamiento
- Hospital Israelita Albert Einstein
-
Investigador principal:
- Guilherme Perini, MD
-
Contacto:
- Correo electrónico: guiperini@gmail.com
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil
- Reclutamiento
- Hospital São Rafael
-
Contacto:
- Cacilda
- Correo electrónico: analuziaschriefer@gmail.com
-
Investigador principal:
- Ana Luiza Schriefer, MD
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil
- Reclutamiento
- Hospital de Clínicas de Porto Alegre
-
Investigador principal:
- Laura Maria Fogliatto, MD
-
Contacto:
- Suellen
- Correo electrónico: fogliattopesquisa@gmail.com
-
-
-
-
-
Barcelona, España
- Reclutamiento
- Institut Català d'Oncologia, L'Hospitalet de Llobregat
-
Investigador principal:
- Eva Domingo Domenech, MD
-
Contacto:
- Correo electrónico: edomingo@iconcologia.net
-
Madrid, España
- Reclutamiento
- University Hospital Fundacion Jimenez Diaz
-
Investigador principal:
- Raul Cordoba Mascunano, MD
-
Contacto:
- Correo electrónico: raul.cordoba@fjd.es
-
-
Barcelona
-
Badalona, Barcelona, España
- Reclutamiento
- Hospital ICO, Trias i Pujol
-
Investigador principal:
- Juan Manuel Sancho Cia, MA
-
Contacto:
- Correo electrónico: jsancho@iconcologia.net
-
Barcelona, Barcelona, España
- Reclutamiento
- Hospital Universitari Vall d'Hebron
-
Investigador principal:
- Pablo Abrisqueta Costa, MD
-
Contacto:
- Correo electrónico: pabrisqueta@vhio.net
-
Barcelona, Barcelona, España
- Reclutamiento
- Hospital de la Santa Creu i Sant Pau, Dep Hematologia
-
Contacto:
- Correo electrónico: smiqueleiz@santpau.cat
-
Investigador principal:
- Sara Miqueleiz Alamos, MD
-
-
Madrid
-
Madrid, Madrid, España
- Reclutamiento
- Hospital Universitario HM Sanchinarro
-
Contacto:
- Agustín Penedo Coello
- Correo electrónico: apenedo@hmhospitales.com
-
Investigador principal:
- Augustin Penedo Coello, MD
-
Madrid, Madrid, España
- Reclutamiento
- Hospital General Universitario Gregorio Marañon-Oncología Médica
-
Investigador principal:
- Mariana Bastos Oreiro, MD
-
Contacto:
- Correo electrónico: bastosmariana@yahoo.com
-
-
Murcia
-
Murcia, Murcia, España
- Aún no reclutando
- Hospital Universitario Virgen de la Arrixaca
-
Investigador principal:
- Joaquin Gomez Espuch, MD
-
Contacto:
- Correo electrónico: joaquingomezespuch@hotmail.com
-
-
Seville
-
Seville, Seville, España
- Reclutamiento
- Hospital University Virgen Macarene
-
Investigador principal:
- Sergio Ortegon Alcaide, MD
-
Contacto:
- Sergio Ortegón Alcaide
- Correo electrónico: sortegonalcaide@gmail.com
-
-
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Activo, no reclutando
- Emory University Hospital
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40207
- Reclutamiento
- Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
-
Investigador principal:
- Don Stevens, MD
-
-
-
-
-
Grudziądz, Polonia, 86-300
- Terminado
- Szpital Specjlistyczny
-
Krakow, Polonia
- Terminado
- Małopolskie Centrum Medyczne
-
-
-
-
-
Lund, Suecia, SE-22185
- Terminado
- Department of Oncology, Skåne University Hospital
-
-
Sweden
-
Uppsala, Sweden, Suecia, 751 85
- Terminado
- Department of Oncology, Academical Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Are ≥ 18 years of age by initiation of study treatment.
- Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL)
- Have measurable nodal disease
- Are willing to undergo lymph node biopsies or biopsies of other involved tissue
- Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists
- Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen
- Have a life expectancy of at least 12 weeks
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Have CD20+ malignancy
- Have hematological and biochemical indices within prespecified ranges
Exclusion Criteria:
-
Have had an allogenic bone marrow or stem cell transplant within 12 months
-
Have presence of active chronic graft versus host disease
-
Have current leptomeningeal lymphoma or compromise of the central nervous system
-
Have transformed lymphoma from a pre-existing indolent lymphoma
-
Have Waldenstrom's Macroglobulinemia or FL grade 3B,
-
Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.
-
Have known or suspected hypersensitivity to rituximab or BI-1206
-
Have cardiac or renal amyloid light-chain amyloidosis
-
Have received any of the following:
- Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
- Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
- Immunotherapy within 8 weeks
- Previous lines of treatment containing BTK inhibitors for Subjects receiving BI-1206 in combination with rituximab and acalabrutinib
-
Have ongoing toxic manifestations of previous treatments.
-
Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).
-
Have had major surgery from which the subject has not yet recovered.
-
Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.
-
Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
-
Have an active, known or suspected autoimmune disease.
-
Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA])
-
Have current malignancies of other types
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: BI-1206 IV Dose Escalation
Standard 3+3 Dose-Escalation of BI-1206 IV in combination with Rituximab |
BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion Rituximab 375 mg/m2, as per SmPC
Otros nombres:
|
|
Experimental: BI-1206 SC Dose Escalation
Adaptive Dose Escalation of BI-1206 SC (Bayesian logistic regression model (BLRM) in combination with Rituximab |
BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion Rituximab 375 mg/m2, as per SmPC
Otros nombres:
|
|
Experimental: Phase 2a IV Dose expansion
BI-1206 IV in Combination with Rituximab |
BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion Rituximab 375 mg/m2, as per SmPC
Otros nombres:
|
|
Experimental: Phase 2a SC Signal seeking
SC Arm, BI-1206 in Combination with Rituximab and Acalabrutinib |
BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion Rituximab 375 mg/m2, as per SmPC
Otros nombres:
Acalabrutinib 100 mg orally as per SmPC
Otros nombres:
|
|
Experimental: Phase 2a IV Signal Seeking
IV Arm, BI-1206 in Combination with Rituximab and Acalabrutinib |
BI-1206 150 mg / 225 mg Subcutaneous injection BI-1206 50 mg /100 mg Intravenous infusion Rituximab 375 mg/m2, as per SmPC
Otros nombres:
Acalabrutinib 100 mg orally as per SmPC
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab and/or acalabrutinib
Periodo de tiempo: During the 28-day treatment period on induction therapy
|
Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab or rituximab and acalabrutinib in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), subtypes follicular lymphoma (FL)(except FL grade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Assessment will be done according to National Cancer Institute (NCI-CTCAE) criteria v. 5.0. |
During the 28-day treatment period on induction therapy
|
|
Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)
Periodo de tiempo: During the 28-day treatment period on induction therapy
|
Phase 1: Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab. |
During the 28-day treatment period on induction therapy
|
|
Determine the recommended dose of BI-1206 in combination with rituximab and acalabrutinib
Periodo de tiempo: During the 28-day treatment period on induction therapy
|
Phase 2a: Select the recommended dose of BI-1206 in combination with rituximab and acalabrutinib. |
During the 28-day treatment period on induction therapy
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluation of PK parameters for BI-1206
Periodo de tiempo: Up to 1 year
|
PK parameters assessed will include AUC, Cmax, time to Cmax and t1/2 of BI-1206 when administered IV or SC |
Up to 1 year
|
|
Evaluation of ADA (immunogenicity) response to BI-1206
Periodo de tiempo: Up to 1 year
|
Assess the incidence and titre of antidrug antibodies of BI-1206 in serum when administered IV or SC in combination with rituximab or rituximab and acalabrutinib. |
Up to 1 year
|
|
Measurement of peripheral blood B-lymphocytes depletion
Periodo de tiempo: Up to 1 year
|
Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib measuring B Lymphocytes CD19+ (absolute value) as part of hematology assessment to determine the level of peripheral blood B lymphocyte depletion. |
Up to 1 year
|
|
Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).
Periodo de tiempo: Up to 1 year
|
Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab or rituximab and acalabrutinib at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy. |
Up to 1 year
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Expression levels of CD32b protein
Periodo de tiempo: Up to 1 year
|
To investigate CD32b protein expression levels using flow cytometry to evaluate any potential correlation with clinical responses. Change from baseline expression levels will be summarized descriptively by dose cohort and/or response to treatment. |
Up to 1 year
|
|
Assessment of Patient Reported Outcomes using the NCI PRO-CTCAE questionnaire
Periodo de tiempo: Up to 1 year
|
The NCI PRO-CTCAE will be used to evaluate symptomatic toxicities reported by patients. The questionnaire characterizes the frequency, severity, interference, and presence/absence of symptomatic toxicities, all toxicities that can be meaningfully reported from the patient perspective. Responses are scored from 0 to 4 (or 0/1 for absent/present). Scores for each attribute (frequency, severity and/or interference) will be presented descriptively (e.g. summary statistics or graphical presentations). |
Up to 1 year
|
|
Expression levels of CD32b and/or other immunological markers
Periodo de tiempo: Up to 1 year
|
Perform whole-transcriptome, quantitative polymerase chain reaction (qPCR) and/or IHC analysis of lymph node biopsies to evaluate potential correlation with clinical responses. |
Up to 1 year
|
|
Measurement of serum cytokines levels and/or soluble CD32b.
Periodo de tiempo: Up to 1 year
|
Study the potential cause of infusion related reactions (IRRs), such as cytokine release signs, C-reactive protein (CRP) and/or soluble CD32b. |
Up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 17-BI-1206-02
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.
Marco de tiempo para compartir IPD
Within one year from end of study
Criterios de acceso compartido de IPD
Paper copy of CSR
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .